

Primary Progressive Aphasia - Pipeline Insight, 2019

<https://marketpublishers.com/r/P29CCFA1F8DEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: P29CCFA1F8DEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Primary Progressive Aphasia - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Progressive Aphasia pipeline landscape is provided which includes the disease overview and Primary Progressive Aphasia treatment guidelines. The assessment part of the report embraces, in depth Primary Progressive Aphasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Progressive Aphasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Primary Progressive Aphasia Understanding

Primary Progressive Aphasia (PPA) is a neurological syndrome in which language capabilities become slowly and progressively impaired. Unlike other forms of aphasia that result from stroke or brain injury, PPA is caused by neurodegenerative diseases, such as Alzheimer's disease or Frontotemporal Lobar Degeneration. PPA results from deterioration of brain tissue important for speech and language. Although the first symptoms are problems with speech and language, other problems associated with the underlying disease, such as memory loss, often occur later. PPA commonly begins as a subtle disorder of language, progressing to a nearly total inability to speak, in its most severe stage. The type or pattern of the language deficit may differ from patient to patient. The initial language disturbance may be fluent aphasia (i.e., the person may have normal or even increased rate of word production) or non-fluent aphasia (speech becomes effortful and the person produces fewer words). A less common variety begins

with impaired word-finding and progressive deterioration of naming and comprehension, with relatively preserved articulation.

Primary Progressive Aphasia Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Primary Progressive Aphasia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Primary Progressive Aphasia pipeline report covers 6+ companies. Some of the key players include Axon Neuroscience (AADvac1) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Primary Progressive Aphasia Analytical Perspective by DelveInsight

In-depth Primary Progressive Aphasia Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Primary Progressive Aphasia Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Primary Progressive Aphasia report provides an overview of therapeutic

pipeline activity for Primary Progressive Aphasia across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Primary Progressive Aphasia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Primary Progressive Aphasia Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Primary Progressive Aphasia

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Primary Progressive Aphasia to formulate effective R&D strategies

Assess challenges and opportunities that influence Primary Progressive Aphasia R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Primary Progressive Aphasia in licensing and out licensing strategies by identifying prospective partners with progressing projects for Primary Progressive Aphasia to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. PRIMARY PROGRESSIVE APHASIA

- 2.1. Primary Progressive Aphasia Disease Overview
- 2.2. Primary Progressive Aphasia History
- 2.3. Primary Progressive Aphasia Symptoms
- 2.4. Primary Progressive Aphasia Causes
- 2.5. Primary Progressive Aphasia Pathophysiology
- 2.6. Primary Progressive Aphasia Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. PRIMARY PROGRESSIVE APHASIA CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. PRIMARY PROGRESSIVE APHASIA - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Primary Progressive Aphasia companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Primary Progressive Aphasia Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Primary Progressive Aphasia Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. PRIMARY PROGRESSIVE APHASIA PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. PRIMARY PROGRESSIVE APHASIA -PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. AADvac1- Axon Neuroscience
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
- To be continued in the report.....

7. RECENT TECHNOLOGIES

8. PRIMARY PROGRESSIVE APHASIA KEY COMPANIES

- 8.1. Axon Neuroscience
- 8.2. GE Healthcare
- 8.3. Eisai Co Ltd
- 8.4. Avid Radiopharmaceuticals
- 8.5. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- 8.6. Alector Inc.

9. PRIMARY PROGRESSIVE APHASIA KEY PRODUCTS

- 9.1. AADvac 1
- 9.2. Fluorine-18-THK 5351
- 9.3. Donepezil
- 9.4. Flortaucipir F 18
- 9.5. galantamine hydrobromide
- 9.6. AL001

10. DORMANT AND DISCONTINUED PRODUCTS

- 10.1. Dormant Products
 - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
 - 10.2.1. Reasons for the discontinuation

11. PRIMARY PROGRESSIVE APHASIA - UNMET NEEDS

12. PRIMARY PROGRESSIVE APHASIA - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

- 14.1. Secondary Research
- 14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Primary Progressive Aphasia Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Primary Progressive Aphasia Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Primary Progressive Aphasia companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Primary Progressive Aphasia Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Axon Neuroscience
GE Healthcare
Eisai Co Ltd
Avid Radiopharmaceuticals

Biogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

IntraBio Inc

Genzyme, a Sanofi Company|Sanofi

FORUM Pharmaceuticals Inc

CTD Holdings, Inc.

Alexion Pharmaceuticals

Alector Inc.

Aldagen

Actelion

I would like to order

Product name: Primary Progressive Aphasia - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/P29CCFA1F8DEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P29CCFA1F8DEN.html>